Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06549751 | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer(PANACEA) | not yet recruiting | Phase 1 | 38 | Marker Therapeutics, Inc.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT06735560 | Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN(ELEGANCE) | recruiting | N/A | 60 | Nantes University HospitalOTHER | 1 | May 13, 2026 |
| clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07532590 | Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus). | recruiting | N/A | 185 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | active not recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07436312 | Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer(U-TRANS) | recruiting | N/A | 170 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07554560 | Nutrition Intervention for Pancreatic Cancer | recruiting | N/A | 18 | Children's Hospital of PhiladelphiaOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06441747 | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | recruiting | Phase 2 | 40 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT07570849 | Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04881487 | Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy(ARCADE) | recruiting | N/A | 174 | UMC UtrechtOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06228599 | Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence(PROTECT-PANC) | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05296421 | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | recruiting | N/A | 16 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | active not recruiting | Phase 2 | 12 | Brandon Huffman, MDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06050317 | Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer | recruiting | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07030140 | Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma | recruiting | Phase 2 | 38 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07099547 | Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561463 | Sacituzumab Tirumotecan for Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07561775 | Adebrelimab Plus S-1 for Resected Cholangiocarcinoma | not yet recruiting | Phase 2 | 40 | Xingjun GuoOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT05043857 | Stereotactic PAncreatic RadioTherapy Adjuvant Therapy(SPARTA) | active not recruiting | N/A | 50 | Istituto Clinico HumanitasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Washington University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07478523 | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers(FAPDIG) | recruiting | Phase 2 | 120 | University Hospital, BordeauxOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07206355 | In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers(Map HPB) | recruiting | — | 160 | University of NottinghamOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555587 | Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC) | not yet recruiting | Phase 1 | 10 | NRT MedTech Australia Pty LtdINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556835 | Outcomes After Liver and Biliary Resection at a High-Volume Center(BILIVER) | not yet recruiting | — | 1,000 | Azienda USL Toscana CentroOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03033927 | Predicting Effective Therapy in Pancreatic Cancer | active not recruiting | — | 74 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04837833 | An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma | active not recruiting | N/A | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06381882 | The Role of the Human Microbiome in Patients After Pancreatic Resection.(MiPac) | enrolling by invitation | — | 200 | St. Antonius HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06549725 | Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening | recruiting | N/A | 419 | Lipidica, a.s.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07408505 | Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer | recruiting | N/A | 56 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07547033 | Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy(EQUINOXE) | not yet recruiting | N/A | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05655949 | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | recruiting | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05973331 | Prospective Validation of an EHR-based Pancreatic Cancer Risk Model | active not recruiting | — | 6,134,060 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06330441 | Pancreatic Cancer Screening in a Population at High Risk(ScrePan) | recruiting | N/A | 700 | Masaryk Memorial Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06705335 | Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma(CONVERCAP) | recruiting | — | 50 | Institut BergoniéOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05179486 | Molecular Epidemiology of Biliary Tree Cancers | recruiting | — | 1,500 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06655142 | OSCAR II STUDY - The ONCObind CTC Removal Study | not yet recruiting | N/A | 120 | ExThera Medical CorporationINDUSTRY | 0 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT04940286 | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05967182 | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06453486 | A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment(ABLATE) | recruiting | Phase 2 | 43 | University Health Network, TorontoOTHER | 1 | Apr 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2026source: clinicaltrials